Skip to main content
Top
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Gastric Cancer | Research

PLCD3 inhibits apoptosis and promotes proliferation, invasion and migration in gastric cancer

Authors: Yantao Yu, Shantanu Baral, Qiannan Sun, Jianyue Ding, Qi Zhang, Fanyu Zhao, Shuyang Gao, Qing Yao, Haoyue Yu, Bin Liu, Daorong Wang

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Gastric cancer (GC) is a heterogeneous disease whose development is accompanied by alterations in a variety of pathogenic genes. The phospholipase C Delta 3 enzyme is a member of the phospholipase C family, which controls substance transport between cells in the body. However, its role in gastric cancer has not been discovered. The purpose of this study was to investigate the expression and mechanism of action of PLCD3 in connection to gastric cancer. By Western blot analysis and immunohistochemistry, PLCD3 mRNA and protein expression levels were measured, with high PLCD3 expression suggesting poor prognosis. In N87 and HGC-27 cells, the silencing of PLCD3 using small interfering RNA effectively induced apoptosis and inhibited tumor cell proliferation, invasion, and migration. Conversely, overexpression of PLCD3 using overexpressed plasmids inhibited apoptosis in AGS and BGC-823 cells and promoted proliferation, migration, and invasion. In order to investigate the underlying mechanisms, we conducted further analysis of PLCD3, which indicates that this protein is closely related to the cell cycle and EMT. Additionally, we found that overexpression of PLCD3 inhibits apoptosis and promotes the development of GC cells through JAK2/STAT3 signaling. In conclusion, PLCD3 inhibits apoptosis and promotes proliferation, invasion, and migration, which indicated that PLCD3 might serve as a therapeutic target for gastric cancer.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
3.
go back to reference Conti CB, Agnesi S, Scaravaglio M, Masseria P, Dinelli ME, Oldani M, Uggeri F. Early gastric cancer: update on prevention, diagnosis and treatment. Int J Environ Res Public Health. 2023;20(3):2149.CrossRefPubMedPubMedCentral Conti CB, Agnesi S, Scaravaglio M, Masseria P, Dinelli ME, Oldani M, Uggeri F. Early gastric cancer: update on prevention, diagnosis and treatment. Int J Environ Res Public Health. 2023;20(3):2149.CrossRefPubMedPubMedCentral
4.
go back to reference Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064.PubMed Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064.PubMed
6.
go back to reference Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC, Bizama C. Molecular classification of gastric cancer: towards a pathway-driven targeted therapy. Oncotarget. 2015;6(28):24750–79.CrossRefPubMedPubMedCentral Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC, Bizama C. Molecular classification of gastric cancer: towards a pathway-driven targeted therapy. Oncotarget. 2015;6(28):24750–79.CrossRefPubMedPubMedCentral
7.
go back to reference Kim H, Suh PG, Ryu SH, Park SH. Assignment of the human PLC delta3 gene (PLCD3) to human chromosome band 17q21 by fluorescence in situ hybridization. Cytogenet Cell Genet. 1999;87(3–4):209–10.CrossRefPubMed Kim H, Suh PG, Ryu SH, Park SH. Assignment of the human PLC delta3 gene (PLCD3) to human chromosome band 17q21 by fluorescence in situ hybridization. Cytogenet Cell Genet. 1999;87(3–4):209–10.CrossRefPubMed
8.
go back to reference Lin L, Wen J, Lin B, Chen H, Bhandari A, Qi Y, Zheng D, Wang O. Phospholipase C Delta 3 inhibits apoptosis and promotes proliferation, migration, and invasion of thyroid cancer cells via Hippo pathway. Acta Biochim Biophys Sin (Shanghai). 2021;53(4):481–91.CrossRefPubMed Lin L, Wen J, Lin B, Chen H, Bhandari A, Qi Y, Zheng D, Wang O. Phospholipase C Delta 3 inhibits apoptosis and promotes proliferation, migration, and invasion of thyroid cancer cells via Hippo pathway. Acta Biochim Biophys Sin (Shanghai). 2021;53(4):481–91.CrossRefPubMed
9.
go back to reference Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. Faseb J. 1995;9(7):484–96.CrossRefPubMed Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. Faseb J. 1995;9(7):484–96.CrossRefPubMed
10.
go back to reference De Smedt H, Parys JB. Molecular and functional diversity of inositol triphosphate-induced Ca(2+)release. Verh K Acad Geneeskd Belg. 1995;57(5):423–58.PubMed De Smedt H, Parys JB. Molecular and functional diversity of inositol triphosphate-induced Ca(2+)release. Verh K Acad Geneeskd Belg. 1995;57(5):423–58.PubMed
12.
go back to reference Fu L, Qin YR, Xie D, Hu L, Kwong DL, Srivastava G, Tsao SW, Guan XY. Characterization of a novel tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous cell carcinoma. Cancer Res. 2007;67(22):10720–6.CrossRefPubMed Fu L, Qin YR, Xie D, Hu L, Kwong DL, Srivastava G, Tsao SW, Guan XY. Characterization of a novel tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous cell carcinoma. Cancer Res. 2007;67(22):10720–6.CrossRefPubMed
13.
go back to reference Hu D, Jiang Z. Phospholipase C δ1 (PLCD1) inhibits the proliferation, invasion and migration of CAPAN-1 and BXPC-3 pancreatic cancer cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016;32(6):739–45.PubMed Hu D, Jiang Z. Phospholipase C δ1 (PLCD1) inhibits the proliferation, invasion and migration of CAPAN-1 and BXPC-3 pancreatic cancer cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016;32(6):739–45.PubMed
14.
go back to reference Liu W, Liu X, Wang L, Zhu B, Zhang C, Jia W, Zhu H, Liu X, Zhong M, Xie D, Liu Y, Li S, Shi J, Lin J, Xia X, Jiang X, Ren C. PLCD3, a flotillin2-interacting protein, is involved in proliferation, migration and invasion of nasopharyngeal carcinoma cells. Oncol Rep. 2018;39(1):45–52.PubMed Liu W, Liu X, Wang L, Zhu B, Zhang C, Jia W, Zhu H, Liu X, Zhong M, Xie D, Liu Y, Li S, Shi J, Lin J, Xia X, Jiang X, Ren C. PLCD3, a flotillin2-interacting protein, is involved in proliferation, migration and invasion of nasopharyngeal carcinoma cells. Oncol Rep. 2018;39(1):45–52.PubMed
15.
go back to reference Sakurai K, Hirata M, Yamaguchi H, Nakamura Y, Fukami K. Phospholipase Cδ3 is a novel binding partner of myosin VI and functions as anchoring of myosin VI on plasma membrane. Adv Enzyme Regul. 2011;51(1):171–81.CrossRefPubMed Sakurai K, Hirata M, Yamaguchi H, Nakamura Y, Fukami K. Phospholipase Cδ3 is a novel binding partner of myosin VI and functions as anchoring of myosin VI on plasma membrane. Adv Enzyme Regul. 2011;51(1):171–81.CrossRefPubMed
16.
go back to reference Li Y, Li X-Y, Li L-X, Zhou R-C, Sikong Y, Gu X, Jin B-Y, Li B, Li Y-Q, Zuo X-L. S100A10 accelerates aerobic glycolysis and malignant growth by activating mTOR-signaling pathway in gastric cancer. Front Cell Dev Biol. 2020;8:559486.CrossRefPubMedPubMedCentral Li Y, Li X-Y, Li L-X, Zhou R-C, Sikong Y, Gu X, Jin B-Y, Li B, Li Y-Q, Zuo X-L. S100A10 accelerates aerobic glycolysis and malignant growth by activating mTOR-signaling pathway in gastric cancer. Front Cell Dev Biol. 2020;8:559486.CrossRefPubMedPubMedCentral
17.
go back to reference Zhang Q, Ali M, Wang Y, Sun QN, Zhu XD, Tang D, Wang W, Zhang CY, Zhou HH, Wang DR. Galectin-1 binds GRP78 to promote the proliferation and metastasis of gastric cancer. Int J Oncol. 2022;61(5):1.CrossRef Zhang Q, Ali M, Wang Y, Sun QN, Zhu XD, Tang D, Wang W, Zhang CY, Zhou HH, Wang DR. Galectin-1 binds GRP78 to promote the proliferation and metastasis of gastric cancer. Int J Oncol. 2022;61(5):1.CrossRef
18.
go back to reference Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.CrossRefPubMed Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.CrossRefPubMed
21.
go back to reference Pawelczyk T, Matecki A. Localization of phospholipase C delta3 in the cell and regulation of its activity by phospholipids and calcium. Eur J Biochem. 1998;257(1):169–77.CrossRefPubMed Pawelczyk T, Matecki A. Localization of phospholipase C delta3 in the cell and regulation of its activity by phospholipids and calcium. Eur J Biochem. 1998;257(1):169–77.CrossRefPubMed
22.
go back to reference Lin FG, Cheng HF, Lee IF, Kao HJ, Loh SH, Lee WH. Downregulation of phospholipase C delta3 by cAMP and calcium. Biochem Biophys Res Commun. 2001;286(2):274–80.ADSCrossRefPubMed Lin FG, Cheng HF, Lee IF, Kao HJ, Loh SH, Lee WH. Downregulation of phospholipase C delta3 by cAMP and calcium. Biochem Biophys Res Commun. 2001;286(2):274–80.ADSCrossRefPubMed
23.
go back to reference Dolley G, Lamarche B, Despres JP, Bouchard C, Perusse L, Vohl MC. Phosphoinositide cycle gene polymorphisms affect the plasma lipid profile in the Quebec family study. Mol Genet Metab. 2009;97(2):149–54.CrossRefPubMed Dolley G, Lamarche B, Despres JP, Bouchard C, Perusse L, Vohl MC. Phosphoinositide cycle gene polymorphisms affect the plasma lipid profile in the Quebec family study. Mol Genet Metab. 2009;97(2):149–54.CrossRefPubMed
24.
go back to reference Kouchi Z, Igarashi T, Shibayama N, Inanobe S, Sakurai K, Yamaguchi H, Fukuda T, Yanagi S, Nakamura Y, Fukami K. Phospholipase Cdelta3 regulates RhoA/Rho kinase signaling and neurite outgrowth. J Biol Chem. 2011;286(10):8459–71.CrossRefPubMed Kouchi Z, Igarashi T, Shibayama N, Inanobe S, Sakurai K, Yamaguchi H, Fukuda T, Yanagi S, Nakamura Y, Fukami K. Phospholipase Cdelta3 regulates RhoA/Rho kinase signaling and neurite outgrowth. J Biol Chem. 2011;286(10):8459–71.CrossRefPubMed
25.
go back to reference Rebecchi MJ, Raghubir A, Scarlata S, Hartenstine MJ, Brown T, Stallings JD. Expression and function of phospholipase C in breast carcinoma. Adv Enzyme Regul. 2009;49(1):59–73.CrossRefPubMed Rebecchi MJ, Raghubir A, Scarlata S, Hartenstine MJ, Brown T, Stallings JD. Expression and function of phospholipase C in breast carcinoma. Adv Enzyme Regul. 2009;49(1):59–73.CrossRefPubMed
26.
go back to reference Mori M, Bogdan A, Balassa T, Csabai T, Szekeres-Bartho J. The decidua-the maternal bed embracing the embryo-maintains the pregnancy. Semin Immunopathol. 2016;38(6):635–49.CrossRefPubMedPubMedCentral Mori M, Bogdan A, Balassa T, Csabai T, Szekeres-Bartho J. The decidua-the maternal bed embracing the embryo-maintains the pregnancy. Semin Immunopathol. 2016;38(6):635–49.CrossRefPubMedPubMedCentral
27.
go back to reference Chen S, Shen Z, Gao L, Yu S, Zhang P, Han Z, Kang M. TPM3 mediates epithelial–mesenchymal transition in esophageal cancer via MMP2/MMP9. Ann Transl Med. 2021;9(16):1338.CrossRefPubMedPubMedCentral Chen S, Shen Z, Gao L, Yu S, Zhang P, Han Z, Kang M. TPM3 mediates epithelial–mesenchymal transition in esophageal cancer via MMP2/MMP9. Ann Transl Med. 2021;9(16):1338.CrossRefPubMedPubMedCentral
28.
29.
go back to reference Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Shetuni B, Barsky SH. ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene. 2010;29(10):1451–62.CrossRefPubMed Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Shetuni B, Barsky SH. ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene. 2010;29(10):1451–62.CrossRefPubMed
30.
go back to reference Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016;8(4):603–19.CrossRefPubMed Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016;8(4):603–19.CrossRefPubMed
31.
go back to reference Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175–93.CrossRefPubMedPubMedCentral Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175–93.CrossRefPubMedPubMedCentral
32.
go back to reference Yang Y, Zhang Q, Liang J, Yang M, Wang Z, Tang D, Wang D. STAM2 knockdown inhibits proliferation, migration, and invasion by affecting the JAK2/STAT3 signaling pathway in gastric cancer. Acta Biochim Biophys Sin (Shanghai). 2021;53(6):697–706.CrossRefPubMed Yang Y, Zhang Q, Liang J, Yang M, Wang Z, Tang D, Wang D. STAM2 knockdown inhibits proliferation, migration, and invasion by affecting the JAK2/STAT3 signaling pathway in gastric cancer. Acta Biochim Biophys Sin (Shanghai). 2021;53(6):697–706.CrossRefPubMed
Metadata
Title
PLCD3 inhibits apoptosis and promotes proliferation, invasion and migration in gastric cancer
Authors
Yantao Yu
Shantanu Baral
Qiannan Sun
Jianyue Ding
Qi Zhang
Fanyu Zhao
Shuyang Gao
Qing Yao
Haoyue Yu
Bin Liu
Daorong Wang
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-00881-w

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine